TICKERNERD
Menu
SMMTSMMTHealthcare · Biotechnology

SMMT Stock Forecast: Summit Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$13
+0.19% on the day

The 17 Wall Street analysts covering Summit Therapeutics, Inc. hold a median 12-month price target of $33 — +155.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 18 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$10.4B
Ticker Nerd rank
18 / 100
Median analyst target
$33
Analysts covering
17
Total return, dividends reinvested
1W
−0.5%
1M
−15.4%
YTD
−25.4%
1Y
−51.8%
From 52W high
−55.5%
From 52W low
+3.9%
$13
$29
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SMMT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Summit Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
18 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
86
Accruals
53
Growth
51
Revisions
32
Volatility
29
Issuance
26
Quality
20
Momentum
20
Size
15

Value (86): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Momentum (20): The shares have been drifting down relative to others.

Size (15): Larger than most of the companies we track — more scrutinised, less often mispriced.

The rank is the raw material. Whether the rules would actually own Summit Therapeutics, Inc. — and when they’d sell — is the membership.

Wall Street

SMMT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SMMT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40Oct 25Jan 26Apr 26Jul 26SMMTHigh $42Median $33Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says17 analysts
10 Buy5 Hold2 Sell
Low $10Median $33High $42

The green dot is the last close — the median target sits +155.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
24 July 2026GuggenheimMaintainsBuy$40 → $38
24 July 2026StifelMaintainsBuy$45 → $38
23 July 2026HC Wainwright & Co.ReiteratesNeutral—
22 May 2026BernsteinInitiatesUnderperform$7.70
22 May 2026BernsteinInitiatesUnderperform—
22 May 2026HC Wainwright & Co.DowngradeNeutral—
22 May 2026HC Wainwright & Co.DowngradeNeutral—
4 May 2026HC Wainwright & Co.MaintainsBuy—
1 May 2026Piper SandlerMaintainsNeutral—
8 Apr 2026StifelInitiatesBuy—
16 Mar 2026JefferiesDowngradeHold—
24 Feb 2026HC Wainwright & Co.MaintainsBuy—
2 Feb 2026HC Wainwright & Co.ReiteratesBuy—
30 Jan 2026CitizensReiteratesMarket Outperform—
17 Dec 2025BarclaysUpgradeEqual-Weight—
18 Nov 2025Wolfe ResearchInitiatesPeer Perform—
22 Oct 2025GuggenheimReiteratesBuy—
21 Oct 2025BarclaysMaintainsUnderweight—
21 Oct 2025HC Wainwright & Co.MaintainsBuy—
20 Oct 2025CitigroupMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

SMMT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
3
Fundamentals

Summit Therapeutics, Inc. (SMMT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
25.0×

Cheaper than 32% of US stocks

Price / sales
—
Price / book
18.5×

Cheaper than 5% of US stocks

EV / EBITDA
−11.1×

Cheaper than 85% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 35% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−192.5%

Higher than 7% of US stocks

Return on assets
−101.6%

Higher than 3% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

SMMT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SMMTSummit Therapeutics, Inc.$10.4B
18
APGEApogee Therapeutics, Inc.$10.1B
45
MDGLMadrigal Pharmaceuticals, Inc.$10.7B
67
KRYSKrystal Biotech, Inc.$10.1B
73
HALOHalozyme Therapeutics, Inc.$9.8B
85
NUVLNuvalent, Inc.$9.7B
—
AXSMAxsome Therapeutics, Inc.$11.2B
74
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SMMT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest SMMT news & analysis

Summit Therapeutics: Upgrading To Hold As Critical Approval Decision Approaches

Seeking Alpha · 31 July 2026neutral

Summit Therapeutics was upgraded from Sell to Hold as the FDA reviews its BLA for ivonescimab, with a decision expected by November 14, 2026. The HARMONI study showed statistically significant progression-free survival but only a favorable trend in overall survival; updated hazard-ratio data of 0.76 was submitted.

Why it matters — SMMT shareholders are nearing a pivotal FDA approval decision on ivonescimab while facing intensifying competition and the lack of any acquisition or major partnership offers.

Summit Therapeutics Flags Going Concern Risk Over Cash Needs

Benzinga · 24 July 2026negative

Summit Therapeutics reported an adjusted loss of 19 cents per share, beating the consensus estimate of a 28-cent loss, but flagged a going-concern risk over its cash needs.

Why it matters — The going-concern warning signals that Summit may not have enough cash to sustain operations, raising uncertainty about the company's financial viability.

SMMT's Q2 Loss Wider Than Expected, Ivonescimab Development in Focus

Zacks Investment Research · 24 July 2026neutral

Summit Therapeutics reported a wider-than-expected Q2 loss with no revenue, while its lead drug candidate ivonescimab continues to advance through late-stage studies, undergoes FDA review, and has gained new development collaborations.

Why it matters — SMMT watchers would care because ivonescimab's clinical and regulatory progress is the primary driver of the company's value, even as the company remains in a pre-revenue stage with widening losses.

Summit Therapeutics Inc. (SMMT) Q2 2026 Earnings Call Transcript

Seeking Alpha · 24 July 2026neutral

Summit Therapeutics Inc. held its Q2 2026 earnings call, and a transcript of the call was published on Seeking Alpha.

Why it matters — An earnings call transcript provides detailed commentary from management on the company's quarterly financial results and business outlook.

FAQ

Frequently asked questions about SMMT stock

What is the SMMT stock price forecast for 2026-2027?

The 17 Wall Street analysts covering Summit Therapeutics, Inc. have a median 12-month price target of $33, with estimates ranging from $9.97 to $42. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SMMT stock a buy right now?

Of the 17 analysts covering Summit Therapeutics, Inc., 10 rate it a Buy, 5 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Summit Therapeutics, Inc. 18 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SMMT?

As at 1 Aug 2026, Summit Therapeutics, Inc. ranks 18 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (86 of 100).

Will SMMT stock go up?

No one can know that. What the data says: the median 12-month target from 17 analysts implies +155.6% from the last close, and Ticker Nerd's factor model ranks Summit Therapeutics, Inc. 18 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SMMT stock forecast for 2030?

No analyst covering Summit Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SMMT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9.97 to $42 over the next 12 months.

How has SMMT stock performed over the past year?

Summit Therapeutics, Inc. returned -51.8% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Summit Therapeutics, Inc. do?

Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicinal therapies designed to be patient, physician, caregiver, and societally friendly.

What is the latest news on SMMT?

The most recent item we track (Seeking Alpha, 31 July 2026): "Summit Therapeutics: Upgrading To Hold As Critical Approval Decision Approaches". Summit Therapeutics was upgraded from Sell to Hold as the FDA reviews its BLA for ivonescimab, with a decision expected by November 14, 2026. The HARMONI study showed statistically significant progression-free survival but only a favorable trend in overall survival; updated hazard-ratio data of 0.76 was submitted.

Company

About Summit Therapeutics, Inc.

Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicinal therapies designed to be patient, physician, caregiver, and societally friendly. Its lead candidate, ivonescimab, is a first-in-class bispecific antibody that simultaneously targets PD-1 and VEGF pathways, advancing immunotherapy combined with anti-angiogenesis for oncology applications. The company is conducting multiple Phase III clinical trials evaluating ivonescimab, including in combination with chemotherapy for EGFR-mutated non-small cell lung cancer (NSCLC) after third-generation TKI therapy, first-line metastatic NSCLC, squamous NSCLC, and first-line unresectable metastatic colorectal cancer. Summit Therapeutics Inc. also pursues collaborations, such as with GSK to combine ivonescimab with investigational therapies in solid tumors including small cell lung cancer. These efforts target serious unmet needs in oncology, particularly lung and colorectal cancers. Founded in 2003 and headquartered in Miami, Florida, Summit Therapeutics Inc. operates in the biotechnology sector with a pipeline centered on next-generation cancer treatments.

CEO Mr. Robert W. Duggan · 265 employees · United States · https://www.smmttx.com